Disease-free survival doubled with osimertinib in patients with non-small cell lung carcinoma Disease-free survival doubled with osimertinib in patients with non-small cell lung carcinoma Pharma News Read more
Pharma News Adjuvant pembrolizumab for patients with resected, high-risk stage III melanoma reduces the ri... Read more
Pharma News Read now: abemaciclib delays disease progression and prolongs survival in HR+/HER2 negative ad... Read more
Pharma News Final overall survival results of SOLAR-1 add to growing body of evidence for alpelisib Read more
Pharma News Promising first results regarding potential new treatment for advanced endometrial cancer Read more
Pharma News Longer survival with camrelizumab treatment of oesophageal squamous cell carcinoma Read more
Pharma News European approval for combination therapy to treat mutated metastatic colorectal cancer Read more